FIA
APGE

FNY Investment Advisers’s Apogee Therapeutics APGE Stock Holding History

FNY Investment Advisers’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$663K Buy
+5,000
New +$450K 0.24% 131

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

FNY Investment Advisers's APGE Position: Q2 2026 in Review

FNY Investment Advisers opened a new position in Apogee Therapeutics (APGE) in Q2 2026: 5,000 shares worth $663K. The stake represents 0.24% of the portfolio and ranks #131 among its holdings.

289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • FNY Investment Advisers held 5,000 shares of Apogee Therapeutics worth $663K as of Q2 2026.
  • Apogee Therapeutics was a new FNY Investment Advisers position in Q2 2026.
  • Apogee Therapeutics made up 0.24% of FNY Investment Advisers's portfolio in Q2 2026, its #131 holding.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.